Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.
Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and lowers the price target fr...
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate o...
-SEC Filing
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accel...
Orchestra BioMed's Virtue® Sirolimus AngioInfusionTM Balloon ("Virtue SAB") is the first non-coated drug-eluting ba...
Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progre...
Blog Post - OBIO | AVIM therapy: Durability, Reversibility, and Reproducibility of Effect September 22, 2025 September 22, 2025...
